Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | November 09, 2018 | November 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date November 09, 2018 · Filed November 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2028-11-09 | Direct | 130,465 |
Reported balance
After 2018-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-09 · Grant · Acquired 130,465 · Balance 130,465 F2: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees of $80,000. F1: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
F2: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees of $80,000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2018 Filed Nov 13, 2018 16:57 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 130,465 | $0.61 Strike: $0.89 | $79,975.05 |
DisclosureSEC source: 0001209191-18-058305 · doc4.xml · derivative · entry 1 Windisch Joerg · CIK 0001735528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,465 Underlying: Common Stock · 130,465 shares Expires 2028-11-09 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Plan in lieu of two years of cash retainer and meeting fees of $80,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 16:58 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-18-052156 · doc4.xml · derivative · entry 1 Windisch Joerg · CIK 0001735528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-21 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on September 21, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:19 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-18-021775 · doc4.xml · derivative · entry 1 Windisch Joerg · CIK 0001735528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-23 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on March 23, 2021, subject to the Reporting Person providing continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.